133 related articles for article (PubMed ID: 19395425)
1. Orosomucoid influences the response to antidepressants in major depressive disorder.
Harley J; Roberts R; Joyce P; Mulder R; Luty S; Frampton C; Kennedy M
J Psychopharmacol; 2010 Apr; 24(4):531-5. PubMed ID: 19395425
[TBL] [Abstract][Full Text] [Related]
2. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
[TBL] [Abstract][Full Text] [Related]
3. Childhood neglect and abuse as predictors of antidepressant response in adult depression.
Johnstone JM; Luty SE; Carter JD; Mulder RT; Frampton CM; Joyce PR
Depress Anxiety; 2009; 26(8):711-7. PubMed ID: 19544315
[TBL] [Abstract][Full Text] [Related]
4. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
5. alpha1-acid glycoprotein in late-life depression: relationship to medical burden and genetics.
Adeoye OM; Ferrell RE; Kirshner MA; Mulsant BH; Seligman K; Begley AE; Reynolds CF; Pollock BG
J Geriatr Psychiatry Neurol; 2003 Dec; 16(4):235-9. PubMed ID: 14653433
[TBL] [Abstract][Full Text] [Related]
6. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder.
Tsai SJ; Hong CJ; Liou YJ; Chen TJ; Chen ML; Hou SJ; Yen FC; Yu YW
Psychiatry Res; 2009 Sep; 169(2):113-7. PubMed ID: 19700204
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
8. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
[TBL] [Abstract][Full Text] [Related]
9. Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder.
Lin CH; Lane HY; Chen CC; Juo SH; Yen CF
Clin J Pain; 2011; 27(9):805-10. PubMed ID: 21677571
[TBL] [Abstract][Full Text] [Related]
10. Eighteen months of drug treatment for depression: predicting relapse and recovery.
Mulder RT; Frampton CM; Luty SE; Joyce PR
J Affect Disord; 2009 Apr; 114(1-3):263-70. PubMed ID: 18805590
[TBL] [Abstract][Full Text] [Related]
11. [Influence of ORM1 polymorphism on serum concentration of free nortriptyline].
Zhang C; Tu ZL; Wang QB; Cheng XL; Zhang PH
Yao Xue Xue Bao; 2007 Aug; 42(8):843-8. PubMed ID: 17944232
[TBL] [Abstract][Full Text] [Related]
12. Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline.
Joyce PR; Mulder RT; McKenzie JM; Luty SE; Cloninger CR
Depress Anxiety; 2004; 19(3):180-6. PubMed ID: 15129420
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder.
Sato Y; Yasui-Furukori N; Nakagami T; Saito M; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):416-8. PubMed ID: 19166896
[TBL] [Abstract][Full Text] [Related]
14. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects.
Pae CU; Mandelli L; Kim TS; Han C; Masand PS; Marks DM; Patkar AA; Steffens DC; De Ronchi D; Serretti A
Biomed Pharmacother; 2009 Mar; 63(3):228-35. PubMed ID: 18502089
[TBL] [Abstract][Full Text] [Related]
16. The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men.
Baghai TC; Schule C; Zill P; Deiml T; Eser D; Zwanzger P; Ella R; Rupprecht R; Bondy B
Neurosci Lett; 2004 Jun; 363(1):38-42. PubMed ID: 15157992
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study.
Fabre LF; Scharf MB; Itil TM
J Clin Psychiatry; 1991 Jun; 52 Suppl():62-7. PubMed ID: 2050651
[TBL] [Abstract][Full Text] [Related]
18. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
Akiskal HS; Benazzi F; Perugi G; Rihmer Z
J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
[TBL] [Abstract][Full Text] [Related]
19. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.
Joyce PR; Mulder RT; Luty SE; McKenzie JM; Miller AL; Rogers GR; Kennedy MA
Int J Neuropsychopharmacol; 2003 Dec; 6(4):339-46. PubMed ID: 14604448
[TBL] [Abstract][Full Text] [Related]
20. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients.
Wehmeier PM; Kluge M; Maras A; Riemann D; Berger M; Kohnen R; Dittmann RW; Gattaz WF
Pharmacopsychiatry; 2005 Jan; 38(1):13-6. PubMed ID: 15706460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
